Preclinical work with Ang2–binding, Tie2-activating antibodies (ABTAA) has demonstrated vessel normalization, reduced metastasis, and enhanced chemotherapy efficacy in multiple tumor models [41]. This evidence concerns the gene TEK and neoplasm.